Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861249 · ClinicalTrials.gov registry record · Phase 2
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01861249: Clinical Trial Phase 2 study, sponsored by Sanofi.
NCT01861249 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01861249, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658
Interventions
- DRUG SAR339658
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Why NCT01861249 stopped before completion
NCT01861249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which SAR339658 is the first listed.
NCT01861249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01861249 about?
NCT01861249 is a clinical study titled "Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)". Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658
What is the current status of trial NCT01861249?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01861249?
The interventions under investigation include: SAR339658 (DRUG).
Who is sponsoring clinical trial NCT01861249?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01861249's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia